Risks After Denosumab Discontinuation Linked to Age and Prior Therapy
Researchers sought to identify potential vertebral fracture and bone loss risk factors after discontinuation of denosumab therapy and initiation of other therapy.
Researchers sought to identify potential vertebral fracture and bone loss risk factors after discontinuation of denosumab therapy and initiation of other therapy.
Researchers sought to investigate the impact of vitamin D-specific variables on indices of bone and mineral metabolism in older adults.
There may be an association between physical activity and osteoporosis prevention among individuals aged at least 65 years.
Researchers determined whether balance and functional mobility predicted bone mineral density in postmenopausal women with osteoporosis and osteopenia.
Researchers assessed the long-term safety and efficacy of denosumab in patients with mild to moderate chronic kidney disease (stages 2 and 3).
Vegans have increased risks for total fractures and some site-specific fractures compared with meat eaters.
Low-dose computed tomography (LDCT) chest scans obtained for other reasons may provide opportunistic screening for osteoporosis.
The COVID-19 pandemic may have negatively impacted osteoporosis management.
For patients with asthma, oral corticosteroid (OCS) and inhaled corticosteroid (ICS) use is associated with an increased risk for osteoporosis and fragility fractures.
In the United States, less than one-quarter of women eligible for bone mineral density testing are screened, leaving many women at risk for fractures.